HAMLET B Share Price Performance
SEK 0
-5.78 (-100.00%)
Price SEK 0
Share Pricen/a
Hamlet BioPharma AB (publ) Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
HAMLET B Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
No trending discussion available.
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Hamlet BioPharma AB (publ) Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Nov 14, 2025
- -0.27
- 100.00%
- -27,346.83%
- 0%
About HAMLET B
- Founded
- 1999
- Employees
- 7
- CEO
- WebsiteView website
Hamlet BioPharma AB (publ) engages in the development of drugs for the treatment and prevention of cancer in Sweden. It is developing HAMLET, a tumoricidal protein-lipid complex formed by two generally regarded as safe (GRAS) molecules found in human milk for various oncology markets, including colon, bladder, and cervix cancers, as well as primary or metastatic brain tumors. The company’s products under development include Alpha1H for the treatment of bladder cancer and brain tumors; and BAMLET for the treatment of colon and oral cancer. The company was formerly known as Hamlet Pharma AB (publ) and changed its name to Hamlet BioPharma AB (publ) in August 2023. Hamlet BioPharma AB (publ) was incorporated in 1999 and is based in Lund, Sweden. Hamlet BioPharma AB (publ) is a subsidiary of Linnane Pharma AB.
